Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Sep 5, 2007
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • male and female subjects age 18 to 60
- • relapsing-remitting course of MS
- • stable treatment with glatiramer acetate at least 6 months prior to inclusion
- Exclusion Criteria:
- • primary or secondary progressive forms of MS
- • clinically relevant heart, lung, liver, kidney diseases
- • regular hepatotoxic co-medication
- • drug addiction
- • alcohol abuse
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Berlin, , Germany
Patients applied
Trial Officials
Judith Bellmann-Strobl, Dr., MD
Principal Investigator
Experimental and Clinical Research Center, Charite University, Berlin, Germany
Friedemann Paul, Prof., MD
Study Director
NeuroCure Clinical Research Center, Charité University, Berlin, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials